Has Amgen Already Won Its BPCIA Dispute With Sandoz?

By Brian Coggio and Ron Vogel (August 2, 2017, 11:12 AM EDT) -- Based on the U.S. Supreme Court's decision in Sandoz Inc. v. Amgen Inc.,[1] many have concluded that a biosimilar applicant has the "option' to disclose its application and manufacturing information to the research sponsor, but need not do so. While Sandoz apparently had this choice, it may be argued that the court's decision will likely require Sandoz to disclose such information to Amgen. This is because the court held that the "requirement" that a biosimilar "must" provide the sponsor with the former's application and manufacturing information is not enforceable by an injunction under federal law, and nothing more. The action was...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!